These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 27017151)

  • 21. Homozygous familial hypercholesterolemia with severe involvement of the aortic valve-A sibling-controlled case study on the efficacy of lipoprotein apheresis.
    Galiano M; Hammersen J; Sauerstein K; Blessing H; Rümmele P; Purbojo A; Schöber M; Moosmann J; Raffelsbauer G; Heibges A; Klingel R
    J Clin Apher; 2020 Jun; 35(3):163-171. PubMed ID: 32163632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
    D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
    Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.
    Raal FJ; Santos RD
    Atherosclerosis; 2012 Aug; 223(2):262-8. PubMed ID: 22398274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
    Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K
    Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical observations and treatment of pediatric homozygous familial hypercholesterolemia due to a low-density lipoprotein receptor defect.
    Huang CH; Chiu PC; Liu HC; Lu YH; Huang JK; Charng MJ; Niu DM
    J Clin Lipidol; 2015; 9(2):234-40. PubMed ID: 25911080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.
    Sjouke B; Kusters DM; Kindt I; Besseling J; Defesche JC; Sijbrands EJ; Roeters van Lennep JE; Stalenhoef AF; Wiegman A; de Graaf J; Fouchier SW; Kastelein JJ; Hovingh GK
    Eur Heart J; 2015 Mar; 36(9):560-5. PubMed ID: 24585268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the unique Chinese W483X mutation in the low-density lipoprotein-receptor gene in young patients with homozygous familial hypercholesterolemia.
    Jiang L; Sun LY; Pan XD; Chen PP; Tang L; Wang W; Zhao LM; Yang SW; Wang LY
    J Clin Lipidol; 2016; 10(3):538-546.e5. PubMed ID: 27206941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening of LDLR and APOB gene mutations in Mexican patients with homozygous familial hypercholesterolemia.
    Hernández Flores TJ; González García JR; Colima Fausto AG; Vázquez Cárdenas NA; Sánchez López Y; Zarate Morales CA; Magaña Torres MT
    J Clin Lipidol; 2018; 12(3):693-701. PubMed ID: 29576406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three patients with homozygous familial hypercholesterolemia: Genomic sequencing and kindred analysis.
    Wong KHY; Levy-Sakin M; Ma W; Gonzaludo N; Mak ACY; Vaka D; Poon A; Chu C; Lao R; Balamir M; Grenville Z; Wong N; Kane JP; Kwok PY; Malloy MJ; Pullinger CR
    Mol Genet Genomic Med; 2019 Dec; 7(12):e1007. PubMed ID: 31617323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
    Drouin-Chartier JP; Tremblay AJ; Bergeron J; Lamarche B; Couture P
    Atherosclerosis; 2018 Mar; 270():26-32. PubMed ID: 29407885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives.
    Rodriguez-Calvo R; Masana L
    J Med Genet; 2019 Nov; 56(11):711-717. PubMed ID: 30877235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy.
    D'Erasmo L; Cefalù AB; Noto D; Giammanco A; Averna M; Pintus P; Medde P; Vigna GB; Sirtori C; Calabresi L; Pavanello C; Bucci M; Sabbà C; Suppressa P; Natale F; Calabrò P; Sampietro T; Bigazzi F; Sbrana F; Bonomo K; Sileo F; Arca M
    Adv Ther; 2017 May; 34(5):1200-1210. PubMed ID: 28432645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marked plaque regression in homozygous familial hypercholesterolemia.
    Reeskamp LF; Nurmohamed NS; Bom MJ; Planken RN; Driessen RS; van Diemen PA; Luirink IK; Groothoff JW; Kuipers IM; Knaapen P; Stroes ESG; Wiegman A; Hovingh GK
    Atherosclerosis; 2021 Jun; 327():13-17. PubMed ID: 34004483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
    Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
    Luirink IK; Hutten BA; Greber-Platzer S; Kolovou GD; Dann EJ; de Ferranti SD; Taylan C; Bruckert E; Saheb S; Oh J; Driemeyer J; Farnier M; Pape L; Schmitt CP; Novoa FJ; Maeser M; Masana L; Shahrani A; Wiegman A; Groothoff JW
    Atherosclerosis; 2020 Apr; 299():24-31. PubMed ID: 32199148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cohort Generation and Characterization of Patient-Specific Familial Hypercholesterolemia Induced Pluripotent Stem Cells.
    Omer L; Hudson EA; Hudgins LC; Boyd NL
    Stem Cells Dev; 2021 Jun; 30(12):632-640. PubMed ID: 34029164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational analysis of the LDLR gene in a cohort of Colombian families with familial hypercholesterolemia.
    López G; Bernal LM; Gelvez N; Gómez LF; Nova A; Sánchez AI; Tamayo ML
    Atherosclerosis; 2018 Oct; 277():434-439. PubMed ID: 30270082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience.
    Aljenedil S; Alothman L; Bélanger AM; Brown L; Lahijanian Z; Bergeron J; Couture P; Baass A; Ruel I; Brisson D; Khoury E; Gaudet D; Genest J
    Atherosclerosis; 2020 Oct; 310():54-63. PubMed ID: 32906018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.